Review Article
Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production
Table 1
Effectiveness against the SARS-CoV-2 Omicron (1.1.529) variant after 2 to 4 vaccine dosesa.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aCumulative data as calculated on populations from either England or Israel (for the 4th dose only). |